Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$0.64 +4.6%	$0.69	$0.54 ▼ $2.22	$6.05M	0.29	935,686 shs	35,717 shs
BPTH Bio-Path	$0.19 -2.3%	$0.17	$0.12 ▼ $3.39	$1.55M	-0.05	993,199 shs	4,015 shs
IXHL Incannex Healthcare	$0.20 -8.3%	$0.29	$0.08 ▼ $3.51	$5.92M	7.64	14.20 million shs	14.62 million shs
RNAZ TransCode Therapeutics	$7.49 -1.1%	$8.72	$6.15 ▼ $1,034.88	$6.21M	1.33	103,088 shs	5,709 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	0.00%	-7.13%	-4.35%	-32.09%	-35.68%
BPTH Bio-Path	0.00%	+2.08%	+6.39%	+16.91%	-90.92%
IXHL Incannex Healthcare	0.00%	+6.26%	+0.64%	-72.61%	-93.74%
RNAZ TransCode Therapeutics	0.00%	+8.61%	+8.61%	-60.97%	-99.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFRI Biofrontera	2.1537 of 5 stars	3.5	3.0	2.3	0.0	0.6
BPTH Bio-Path	1.8264 of 5 stars	3.5	3.0	0.0	0.0	1.3
IXHL Incannex Healthcare	0.2082 of 5 stars	0.0	4.0	0.0	0.8	0.0
RNAZ TransCode Therapeutics	1.5005 of 5 stars	3.5	3.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRI Biofrontera	3.00	Buy	$2.75	329.69% Upside
BPTH Bio-Path	3.00	Buy	$20.00	10,589.47% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
RNAZ TransCode Therapeutics	3.00	Buy	$280.00	3,640.81% Upside

Current Analyst Ratings Breakdown

Latest BPTH, BFRI, IXHL, and RNAZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/19/2025	BFRI Biofrontera	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $2.75
4/16/2025	RNAZ TransCode Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$560.00 ➝ $280.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRI Biofrontera	$37.32M	0.16	N/A	N/A	$0.57 per share	1.12
BPTH Bio-Path	N/A	N/A	N/A	N/A	$0.71 per share	N/A
IXHL Incannex Healthcare	$10K	591.54	N/A	N/A	$0.18 per share	1.12
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	($54.96) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRI Biofrontera	-$17.76M	-$2.26	N/A	N/A	N/A	-30.33%	-305.13%	-82.67%	8/13/2025 (Estimated)
BPTH Bio-Path	-$16.08M	N/A	0.00	N/A	N/A	N/A	-2,842.40%	-337.48%	8/13/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	N/A
RNAZ TransCode Therapeutics	-$16.75M	N/A	0.00	N/A	N/A	N/A	-578.88%	-222.61%	N/A

Latest BPTH, BFRI, IXHL, and RNAZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q4 2024	RNAZ TransCode Therapeutics	-$2.00	-$0.60	+$1.40	-$2.51	$0.30 million	N/A
5/15/2025	Q1 2025	BFRI Biofrontera	-$0.14	-$0.47	-$0.33	-$0.47	$10.55 million	$8.59 million
5/15/2025	Q3 2025	IXHL Incannex Healthcare	-$0.46	-$0.24	+$0.22	-$0.20	$0.16 million	$0.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
BPTH Bio-Path	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRI Biofrontera	8.99	1.40	0.80
BPTH Bio-Path	N/A	0.86	0.86
IXHL Incannex Healthcare	N/A	2.12	2.12
RNAZ TransCode Therapeutics	N/A	5.20	5.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRI Biofrontera	10.08%
BPTH Bio-Path	5.74%
IXHL Incannex Healthcare	0.43%
RNAZ TransCode Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BFRI Biofrontera	1.20%
BPTH Bio-Path	0.72%
IXHL Incannex Healthcare	15.49%
RNAZ TransCode Therapeutics	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRI Biofrontera	70	9.45 million	9.33 million	No Data
BPTH Bio-Path	10	8.31 million	5.73 million	Optionable
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable
RNAZ TransCode Therapeutics	9	830,000	832,000	Not Optionable

BPTH, BFRI, IXHL, and RNAZ Headlines

Recent News About These Companies

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

May 28, 2025 | prnewswire.com

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

May 8, 2025 | prnewswire.com

TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 6, 2025 | finanznachrichten.de

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 5, 2025 | prnewswire.com

TransCode Therapeutics approves reverse stock split to meet Nasdaq rules

May 4, 2025 | investing.com

TransCode reports progress in metastatic cancer trial

May 3, 2025 | uk.investing.com

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 2, 2025 | prnewswire.com

IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

May 2, 2025 | finance.yahoo.com

TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

May 2, 2025 | financial-news.co.uk

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

May 1, 2025 | prnewswire.com

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

April 21, 2025 | prnewswire.com

All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy

April 18, 2025 | zacks.com

Transcode Therapeutics price target lowered to $10 from $20 at H.C. Wainwright

April 17, 2025 | markets.businessinsider.com

Transcode Therapeutics begins dosing in fourth cohort of Phase 1 cancer trial

March 28, 2025 | markets.businessinsider.com

TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

March 28, 2025 | finanznachrichten.de

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

March 27, 2025 | prnewswire.com

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

March 25, 2025 | prnewswire.com

Transcode to sell 10.25M shares at 98c per share in registered direct offering

March 25, 2025 | markets.businessinsider.com

TransCode Therapeutics stock slides after announces to raise $10M securities offering

March 24, 2025 | msn.com

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

March 23, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH, BFRI, IXHL, and RNAZ Company Descriptions

Biofrontera NASDAQ:BFRI

$0.64 +0.03 (+4.58%)

As of 01:11 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Bio-Path NASDAQ:BPTH

$0.19 0.00 (-2.30%)

As of 11:49 AM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Incannex Healthcare NASDAQ:IXHL

$0.20 -0.02 (-8.26%)

As of 01:13 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

TransCode Therapeutics NASDAQ:RNAZ

$7.48 -0.09 (-1.12%)

As of 01:13 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time